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In February 2003 The World Health Organization (WHO)
announced that a new pathogen – a member of the coro-
navirus (CoV) family – is the cause of severe acute respira-
tory syndrome (SARS), a mysterious atypical pneumonia
that emerged in China's Guangdong province three
months earlier. Over the next weeks, the illness spread to
more than two dozen countries in Asia, North America,
South America, and Europe, resulting in over 8000 indi-
viduals becoming infected; 774 of which died. Currently,
significant efforts in the area of SARS vaccine research are
being made. Several neutralizing antibodies have been
isolated and reported to prevent viral infection, mainly,
via blocking the association between the viral spike pro-
tein and its cellular receptor, angiotensin converting-
enzyme 2 (ACE-2). Here we report the first steps toward
identifying a major neutralizing epitope of SARS-CoV,
using an original reverse immunological approach.
According to this approach, a neutralizing monoclonal
antibody (mAb) serves as a template for the ultimate pro-
duction of an epitope-based vaccine. In order to accom-
plish this task one must backtrack from the antibody of
interest to its corresponding neutralizing epitope. Once
identified, the epitope can be reconstituted and used to
elicit antibodies with neutralizing activity characteristic of
the original mAb. 80R [1], is a highly potent neutralizing
human anti-SARS mAb directed against the viral spike
protein and has been used to affinity select panels of mAb
specific peptides from phage displayed random peptide
libraries. "Mapitope" [2], a unique computer algorithm,
uses these peptides as input and has enabled us to map
the 80R epitope on the spike protein. In general, Map-
itope prediction of an epitope is based on the notion that
the panel of affinity selected peptides collectively repre-
sents the epitope of the mAb which they bind. More spe-
cifically, pairs of amino acids enriched in the peptide
panels are taken to effectively represent surface accessible
discontinuous pairs of residues of the epitope, juxtaposed
in the antigen via protein folding. Two independent pep-
tide-panels were analyzed against the crystalline structure
of the receptor binding domain (RBD) of the SARS-CoV
spike protein by Mapitope [3]. Three clusters (A, B and C)
were predicted as potential epitopes. Cluster A ranked the
highest, and is currently being considered for reconstitu-
tion and epitope based vaccine production.
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